{
    "clinical_study": {
        "@rank": "50429", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1: Palbociclib under fed conditions", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Cohort 2: Palbociclib under fed conditions", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "To investigate the effect of acid reducing agents (an antacid and an H2-receptor antagonist\n      and a proton pump inhibitor) on palbociclib bioavailability in the presence of food."
        }, 
        "brief_title": "Study Of Three Different Stomach Acid Reducing Agents When Given With Palbociclib (PD-0332991) And Food", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male and/or female subjects of non-childbearing potential between the ages of\n             18 and 55 years, inclusive.\n\n          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110\n             lbs).\n\n          -  Willing and able to comply with all scheduled visits, treatment plan, laboratory\n             tests, and other study procedures.\n\n        Exclusion Criteria:\n\n          -  Evidence or history of clinically significant diseases (hematological, renal,\n             endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric,\n             neurologic, or allergic disease).\n\n          -  Use of tobacco or nicotine containing products within 3 months of screening.\n\n          -  A positive urine drug screen."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02097329", 
            "org_study_id": "A5481038"
        }, 
        "intervention": [
            {
                "arm_group_label": "Cohort 1: Palbociclib under fed conditions", 
                "description": "125 mg oral capsule single dose", 
                "intervention_name": "palbociclib commercial free base", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohort 1: Palbociclib under fed conditions", 
                "description": "20 mg oral tablet 10 hours before and 2 hours after palbociclib", 
                "intervention_name": "famotidine", 
                "intervention_type": "Drug", 
                "other_name": "Pepcid"
            }, 
            {
                "arm_group_label": "Cohort 1: Palbociclib under fed conditions", 
                "description": "2 x 20 mg oral tablets daily for 6 days then on 7th day, 4 hours after palbociclib", 
                "intervention_name": "rabeprazole", 
                "intervention_type": "Drug", 
                "other_name": "Aciphex"
            }, 
            {
                "arm_group_label": "Cohort 2: Palbociclib under fed conditions", 
                "description": "125 mg oral capsule single dose", 
                "intervention_name": "palbociclib commercial free base", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohort 2: Palbociclib under fed conditions", 
                "description": "30 mL orally once (2h before palbociclib)", 
                "intervention_name": "antacid", 
                "intervention_type": "Drug", 
                "other_name": "Mi-Acid Maximum Strength Liquid"
            }, 
            {
                "arm_group_label": "Cohort 2: Palbociclib under fed conditions", 
                "description": "30 mL orally once (2h after palbociclib)", 
                "intervention_name": "antacid", 
                "intervention_type": "Drug", 
                "other_name": "Mi-Acid Maximum Strength Liquid"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antacids", 
                "Anti-Ulcer Agents", 
                "Famotidine", 
                "Rabeprazole", 
                "Proton Pump Inhibitors"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "bioavailability", 
            "antacid", 
            "rabeprazole", 
            "famotidine", 
            "palbociclib"
        ], 
        "lastchanged_date": "May 22, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A5481038&StudyName=Study%20Of%20Three%20Different%20Stomach%20Acid%20Reducing%20Agents%20When%20Given%20With%20Palbociclib%20%28PD-0332991%29%20And%20Food"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "New Haven", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06511"
                }, 
                "name": "Pfizer Investigational Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Open-Label, 3-Period Crossover Study Of The Effect Of An Antacid, A Proton Pump Inhibitor And An H2-Receptor Antagonist On Palbociclib (PD-0332991) Bioavailability Under Fed Conditions In Healthy Volunteers", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "AUC (0 - 8)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - 8). It is obtained from AUC (0 - t) plus AUC (t - 8).", 
                "measure": "Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)]", 
                "safety_issue": "No", 
                "time_frame": "6 days"
            }, 
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "6 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02097329"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)", 
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)", 
                "safety_issue": "No", 
                "time_frame": "6 days"
            }, 
            {
                "description": "Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.  Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling.  Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.", 
                "measure": "Apparent Oral Clearance (CL/F)", 
                "safety_issue": "No", 
                "time_frame": "6 days"
            }, 
            {
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "6 days"
            }, 
            {
                "description": "Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.", 
                "measure": "Apparent Volume of Distribution (Vz/F)", 
                "safety_issue": "No", 
                "time_frame": "6 days"
            }, 
            {
                "description": "Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.", 
                "measure": "Plasma Decay Half-Life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "6 days"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}